Intratumoral heterogeneity, or the genetic diversity among cells inside a tumor, holds the possibility of answering unanswered problems in cancer biology and improving the detection and treatment of certain cancer subtypes. Single-cell analysis, particularly RNA sequencing and other genomics techniques, have been essential in identifying new biomarkers and molecular regulators linked to tumor development, metastasis, and treatment resistance.
However, because information on cellular location within the tumor microenvironment is lost, these methods fail to offer a full picture of tumor biology. The identification of a large number of molecular biomarkers in their original geographical context is now possible because of new methods that use multiplexed fluorescence, DNA, RNA, and isotope labeling. The rapid advancement of these tools, as well as ways for integrating multi-omics data, promises to lead to a better knowledge of cell-to-cell variation inside and across individual tumors.
In this research topic, we will focus on the application and innovation of spatial omics technologies in oncology. We welcome submissions of Original Research papers and Reviews focusing on but not limited to:
- Clinical oncology research and development of tumor diagnosis technology based on
spatial omics.
-Precision clinical oncology research based on spatial omics.
-Application Research of clinical oncology spatial omics.
-Comprehensive clinical oncology research combined with multi-omics techniques.
-Innovation of new spatial omics technology or improvement of original technology.
-Application of artificial intelligence in spatial data interpretation
Please note: manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) will not be accepted in any of the sections of Frontiers in Oncology
Intratumoral heterogeneity, or the genetic diversity among cells inside a tumor, holds the possibility of answering unanswered problems in cancer biology and improving the detection and treatment of certain cancer subtypes. Single-cell analysis, particularly RNA sequencing and other genomics techniques, have been essential in identifying new biomarkers and molecular regulators linked to tumor development, metastasis, and treatment resistance.
However, because information on cellular location within the tumor microenvironment is lost, these methods fail to offer a full picture of tumor biology. The identification of a large number of molecular biomarkers in their original geographical context is now possible because of new methods that use multiplexed fluorescence, DNA, RNA, and isotope labeling. The rapid advancement of these tools, as well as ways for integrating multi-omics data, promises to lead to a better knowledge of cell-to-cell variation inside and across individual tumors.
In this research topic, we will focus on the application and innovation of spatial omics technologies in oncology. We welcome submissions of Original Research papers and Reviews focusing on but not limited to:
- Clinical oncology research and development of tumor diagnosis technology based on
spatial omics.
-Precision clinical oncology research based on spatial omics.
-Application Research of clinical oncology spatial omics.
-Comprehensive clinical oncology research combined with multi-omics techniques.
-Innovation of new spatial omics technology or improvement of original technology.
-Application of artificial intelligence in spatial data interpretation
Please note: manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) will not be accepted in any of the sections of Frontiers in Oncology
